The global leader in corticosteroid APIs opens its Rs 1,757.30 crore mainboard issue on August 24 — 38.2% global market share in corticosteroids, 30+ years of expertise
Symbiotec Pharmalab Ltd. (SPL) sits at a highly specialised corner of the global pharmaceutical value chain — the manufacture of corticosteroid and steroidal-hormone Active Pharmaceutical Ingredients (APIs). These are the molecules that go into drugs treating respiratory conditions, dermatology issues, oncology, pain management, gynaecology and hormone replacement therapies. They are complex to make, tightly regulated, and where SPL has quietly built a genuinely dominant global position.
The scale of leadership is worth pausing on. SPL holds a 38.2% global volume market share in corticosteroids and 23.8% in steroidal hormones in FY26. In specific molecules the dominance is even sharper — 80.1% global volume share in Hydrocortisone, 76.4% in Testosterone and 76.0% in Methylprednisolone. Its market share in Clobetasol Propionate has grown to 50.0% in FY26 from 38.5% in FY25. These are the kind of numbers that most Indian pharma companies would give anything for in any single molecule — SPL has them across a whole portfolio.
The company has a portfolio of over 60 APIs across sterile and non-sterile formats, and is present across 90% of corticosteroid and steroidal-hormone API products. It is the only Indian and global company with a presence across the top 10 APIs in these categories — a market position that has taken over 30 years to build.
The manufacturing model is what makes SPL genuinely differentiated. The company has built a vertically integrated ‘farm/microbe-to-pharmacy’ platform combining organic chemistry, biotechnology and complex injectables. Backward integration allows in-house production of key starting materials for over 80% of its products by revenue — reducing dependence on external suppliers, enabling cost-efficient sourcing and providing supply-chain security. Very few global pharma companies operate this way.
The company has four manufacturing facilities in Madhya Pradesh — Rau (92 MT chemical synthesis for sterile and non-sterile corticosteroid APIs), Pithampur (492.7 MT chemical synthesis and 300 KL fermentation for steroidal-hormone and corticosteroid APIs), Ujjain (400 KL fermentation for large-volume industrial biotechnology, commissioned FY26) and Mhow (20 million double-chamber vials per annum for complex injectables, commissioned FY26). The Rau and Pithampur facilities hold approvals from US FDA, WHO-GMP and EU-GMP — regulatory grade that unlocks the world’s most demanding markets.
The revenue mix is diversified across three business verticals. API products contributed 96.1% of FY26 revenue (Rs 8,350 million), CDMO services a small but growing 0.1% (Rs 11 million, up from zero in FY24), and complex injectables 3.8% (Rs 331 million, a new business). The API base gives stability; the newer verticals give growth optionality.
The customer relationships are exceptionally sticky. SPL served over 200 customers across more than 40 countries in FY26, including leading generic and specialty pharmaceutical companies. Its top 5 customers have relationships of over 10 years on average, and top 10 customers over 9 years. Customers with 7+ year relationships contributed Rs 6,040 million or 69.5% of FY26 revenue — that is deep, structural stickiness. The company added 101 new customers in FY26, up from 96 in FY25 and 89 in FY24.
Geographically, 67.0% of FY26 revenue came from international markets — Europe 29.1%, USA 13.1%, Rest of World 24.8% — and 33.0% from India. The USA jumped sharply from 4.0% in FY25 to 13.1% in FY26, showing strong momentum in the world’s largest pharmaceutical market.
The R&D backbone is meaningful. SPL operates three dedicated R&D centres in Indore with 156 scientists and engineers, including 117 with master’s degrees and 10 PhDs. R&D spending was 3.4% of FY26 revenue — significant for an API business.
The company is expanding into higher-value complex injectables (double-chamber vials, bags and syringes), fermentation-based APIs including GLP-1 and Insulin, and generic conjugated estrogens — all higher-margin, more technically differentiated categories than commodity APIs.
As of March 31, 2026, SPL had over 2,500 employees. It is led by Promoter, Chairman and MD Anil Satwani, who brings 30 years of pharmaceutical industry experience.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | August 24, 2026 |
| Issue Closes | August 27, 2026 |
| Listing | BSE, NSE (Mainboard) |
| Price Band | Rs 938 – Rs 988 per share |
| Face Value | Rs 2 |
| Issue Size | Rs 1,757.30 crore |
| Fresh Issue | Rs 150.30 crore (15.2 lakh shares) |
| OFS | Rs 1,607.00 crore (162.7 lakh shares) |
| Lot Size | 15 shares (multiples thereafter) |
| Min. Retail Investment | Rs 14,820 |
| Post-IPO Market Cap | Rs 6,244.40 crore |
| BRLMs | JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, Nomura Financial Advisory and Securities |
| Registrar | MUFG Intime India Pvt. Ltd. |
From the fresh proceeds of Rs 150.30 crore, the money is earmarked for pre-payment or scheduled repayment of certain borrowings and general corporate purposes.
Note that the OFS component at Rs 1,607 crore is significantly larger than the fresh issue of Rs 150.30 crore — meaning the vast majority of the issue goes to selling shareholders rather than into the business. Post-IPO, promoter and promoter group shareholding drops sharply from 36.4% to just 9.8%, with public shareholding rising to 90.2%. This is a substantial promoter exit event.
GMP Watch
Grey market interest has been moderate. Symbiotec Pharmalab IPO GMP is around Rs 50-70 in the days leading up to the issue opening, suggesting an estimated listing price of around Rs 1,038-1,058 — a modest premium of roughly 5-7% over the upper price band of Rs 988.
This is a lukewarm signal by mainboard IPO standards for a pharma play of this quality, and likely reflects investor caution around the fully-priced valuation (P/E 56.9x) and the large OFS component. GMP is unofficial, unregulated by SEBI and quick to change — treat it as one data point, not a listing forecast.
Financial Performance
| Particulars (Rs cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue from Operations | 716.2 | 751.6 | 869.1 |
| EBITDA | 171.3 | 201.9 | 237.8 |
| PAT | 100.1 | 96.8 | 109.9 |
| EBITDA Margin | 23.9% | 26.9% | 27.4% |
| PAT Margin | 14.0% | 12.9% | 12.6% |
| Sales Growth | – | 4.9% | 15.6% |
Revenue has grown from Rs 716.2 crore in FY24 to Rs 869.1 crore in FY26 — a steady but not spectacular 21% jump in two years. The FY25 revenue growth of just 4.9% is worth noting; it accelerated to 15.6% in FY26. This is not a hyper-growth company — it is a steady global market leader.
PAT has moved narrowly — from Rs 100.1 crore in FY24 to Rs 96.8 crore in FY25 to Rs 109.9 crore in FY26. PAT margins have actually softened from 14.0% to 12.6%, while EBITDA margins have expanded from 23.9% to 27.4%. The gap reflects rising depreciation (from Rs 388 million to Rs 533 million) and interest costs (from Rs 72 million to Rs 253 million) — both signs of the significant capex undertaken to commission the Ujjain and Mhow facilities.
RoE has softened from 15.0% in FY24 to 11.2% in FY26, and RoCE from 14.0% to 11.6% — reflecting the same story. The newly commissioned capacities are not yet contributing revenue but are dragging down return ratios in the near term. As these ramp up, both should recover.
The balance sheet has actually improved. Total borrowings have come down from Rs 5,409 million in FY25 to Rs 3,879 million in FY26, and net debt to EBITDA has fallen from 2.51x to 1.64x. Working capital days have stayed around 78 days in FY26.
Average EPS across three years is about Rs 16.2 and average RoNW is around 12.9%. At the upper band of Rs 988, the P/E works out to 56.9x on FY26 earnings, with an EV/EBITDA of 27.85x — a rich multiple for a pharma company with SPL’s growth profile, though defensible given the moat.
Listed peers Concord Biotech, Divi’s Laboratories, Cohance Lifesciences and Laurus Labs trade at P/E multiples of 61.1, 87.8, 95.0 and 109.4 respectively (as of the report date) — meaning SPL at 56.9x is actually the cheapest among these peers. This peer comparison gives the valuation some cover.
According to a note by Anand Rathi Research, “Symbiotec has established a differentiated position in the global pharmaceutical manufacturing landscape through its strong presence in corticosteroid and steroidal-hormone APIs, where it held global volume market shares of 38.2% and 23.8%, respectively, in FY26. Its integrated capabilities across organic chemistry, biotechnology and complex injectables, supported by backward integration, fermentation expertise and regulatory approvals across key global markets, provide a strong competitive moat. At the upper price band, the company is valuing at P/E of 56.9x and EV/EBITDA of 27.85x with to its FY26 earnings and market cap of Rs 62,444 million post issue of equity shares. We believe that the IPO is fully priced and recommend a ‘Subscribe – Long Term’ rating to the IPO.”
Risks to Consider
API sales constituted 96.07% of FY26 revenue, and the top 5 APIs contributed 62.27%. Any pricing pressure, patent challenge or demand slowdown in these key molecules could hit revenue meaningfully.
Export concentration at 67.04% of FY26 revenue (up from 55.19% in FY25) brings geopolitical, regulatory, currency and trade-related risks. The USA rose sharply to 13.1% of revenue from 4.0% — exciting growth, but also fresh exposure to potential US tariffs or anti-outsourcing measures.
Raw material import dependence is high. Raw material imports accounted for 26.32% of FY26 total expenses, including 23.88% from China — meaningful geopolitical and trade risk exposure. Supplier concentration is also notable, with top 10 suppliers accounting for 25.50% of expenses.
Under-utilisation risk exists on the new capacities. FY26 capacity utilisation was 63.49% at Rau, 83.47% at Pithampur chemical synthesis, and 72.91% at Pithampur fermentation — decent but not maxed out. The newly commissioned Ujjain and Mhow facilities will take time to ramp up, and any delay in customer approvals or demand off-take could hurt returns.
Working capital remained significant at Rs 2,750.50 million in FY26, with current ratio declining to 0.92x — tighter short-term liquidity that needs watching.
Trade receivable days increased to 78 days in FY26 from 61 days in FY24, raising some counterparty credit risk.
The very large OFS at Rs 1,607 crore versus fresh issue of Rs 150.30 crore, combined with promoter holding dropping from 36.4% to 9.8%, represents a substantial promoter dilution that investors should factor in.